Elutia (ELUT) Total Equity: History & Chart

Elutia Inc(ELUT)

Biotechnology · Gaithersburg, MD

$0.82-0.00 (-0.21%)

Delayed quote: Oct 6, 2026, 11:34 AM EDT

About Elutia Inc

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.

Gaithersburg, MD

26 employees

elutia.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: C. Randal Mills

View full financials

Total Equity

Basis: latest reported fiscal quarter. Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly total equity is $15.75M with QoQ Growth of (30.10%). Total equity, also called shareholders' equity, is assets minus liabilities. The book value in P/B is the part attributable to common shareholders: total equity minus preferred stock.

Total Equity

ELUT Total Equity

$15.75M

Reported quarterly total equity; no daily interpolation. Q2 FY2026 (2026-06-30): $15.75M.

+100.36% over 10Y

ELUT P/B Ratio

Full P/B Ratio page

P/B Ratio

ELUT P/B Ratio Chart

2.30

FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock) Quote observation: 2026-10-06T15:36:30.253Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.

Quarterly Total Equity History

Period	Total Equity	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$15.75M	(30.10%)	N/A
Q1 FY2026Period end 2026-03-31	$22.53M	(18.59%)	N/A
Q4 FY2025Period end 2025-12-31	$27.67M	N/A	N/A
Q3 FY2025Period end 2025-09-30	($43.92M)	(4.96%)	(9.15%)
Q2 FY2025Period end 2025-06-30	($41.84M)	(14.77%)	+34.96%
Q1 FY2025Period end 2025-03-31	($36.46M)	+21.19%	+27.52%
Q4 FY2024Period end 2024-12-31	($46.26M)	(14.97%)	(19.84%)
Q3 FY2024Period end 2024-09-30	($40.24M)	+37.46%	(36.52%)
Q2 FY2024Period end 2024-06-30	($64.34M)	(27.91%)	(190.75%)
Q1 FY2024Period end 2024-03-31	($50.30M)	(30.31%)	(313.13%)
Q4 FY2023Period end 2023-12-31	($38.60M)	(30.97%)	(666.94%)
Q3 FY2023Period end 2023-09-30	($29.47M)	(33.19%)	(175.94%)
Q2 FY2023Period end 2023-06-30	($22.13M)	(81.75%)	N/A
Q1 FY2023Period end 2023-03-31	($12.18M)	(141.90%)	N/A
Q4 FY2022Period end 2022-12-31	($5.03M)	+52.88%	N/A
Q3 FY2022Period end 2022-09-30	($10.68M)	N/A	N/A
Q2 FY2022Period end 2022-06-30	($1.37M)	N/A	N/A
Q1 FY2022Period end 2022-03-31	$6.56M	(51.49%)	N/A
Q4 FY2021Period end 2021-12-31	$13.52M	+72.04%	N/A
Q3 FY2021Period end 2021-09-30	$7.86M	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.